CEO total pay
$5,686,740
Samraat S. Raha · 2025
Say on pay
92%
Latest disclosed shareholder vote
CEO pay ratio
Item 402(u)60 to 1
Median employee: $97,407
Compensation committee
CD&ACompensation and Human Capital Committee
Per the latest proxy
Filings indexed: 2 · 2026 · 2025
Executive pay
What did they pay them?
From the Summary Compensation Table. Pay mix and YoY are computed from these rows.
| Executive | Role | TotalYoY | Pay mix | Salary | Stock | Cash incentive | Other |
|---|---|---|---|---|---|---|---|
Samraat S. Raha2025 compensation | President and Chief Executive Officer | $5,686,740↑ 30% | 84% at-risk | $856,901 | $3,989,729 | $814,660 | $25,450 |
Paul J. Diaz2025 compensation | Former President and Chief Executive Officer | $688,637↓ 95% | 0% at-risk | $418,103 | $— | $— | $270,534 |
Scott J. Leffler2025 compensation | Former Chief Financial Officer | $2,736,493↓ 56% | 39% at-risk | $393,798 | $1,067,674 | $— | $1,275,021 |
Benjamin R. Wheeler2025 compensation | Chief Financial Officer | $1,507,897 | 72% at-risk | $408,493 | $759,229 | $325,421 | $14,754 |
Brian J. Donnelly2025 compensation | Chief Commercial Officer | $6,000,145 | 94% at-risk | $350,000 | $4,801,898 | $371,910 | $26,337 |
Mark S. Verratti2025 compensation | Chief Operating Officer | $3,145,251↓ 15% | 79% at-risk | $622,883 | $2,058,069 | $438,323 | $25,976 |
Margaret Ancona2025 compensation | Former EVP, Strategy and Transformation | $1,895,166 | 42% at-risk | $330,850 | $800,754 | $— | $763,561 |
Dale Muzzey, Ph.D.2025 compensation | Chief Scientific Officer | $1,862,912↓ 38% | 72% at-risk | $506,400 | $1,121,054 | $221,677 | $13,781 |
Pay mix: base cash incentive equity other
CD&A excerpt
Compensation discussion & analysis
Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.
Read the full CD&A on SEC.gov ↗
Peer comparison
Who they benchmark against
Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.
Peer Group
17 members · 3 in ProxyMiner
ACAD · ACADIA PHARMACEUTICALS INCIONS · IONIS PHARMACEUTICALS INCALKS · Alkermes plc.IRWD · IRONWOOD PHARMACEUTICALS INCBMRN · BIOMARIN PHARMACEUTICAL INCNTRA · Natera, Inc.TECH · BIO-TECHNE CorpNEO · NEOGENOMICS INCCHRS · Coherus Oncology, Inc.NBIX · NEUROCRINE BIOSCIENCES INCPTCT · PTC THERAPEUTICS, INC.SRPT · Sarepta Therapeutics, Inc.EXEL · EXELIXIS, INC.UTHR · UNITED THERAPEUTICS CorpGH · Guardant Health, Inc.VNDA · Vanda Pharmaceuticals Inc.VCYT · VERACYTE, INC.
Governance
Policy guardrails
hedging
prohibited
“Prohibit hedging transactions for all employees (no waivers granted)”
pledging
prohibited
“Prohibit pledging or the use of common stock to secure a margin or other loan (no waivers granted)”
clawback
present
“clawback policy”
stock ownership guidelines
present
“stock ownership guidelines is measured on the last day of each calendar year. As of December 31, 2025, all of our directors and executive officers were in compliance with the stock ownership requirements or have addition…”
change in control
The terms of the Severance and Change of Control Agreements include
“The terms of the Severance and Change of Control Agreements include”
compensation consultant
independent
“Retain an independent compensation consultant”
compensation committee
Compensation and Human Capital Committee
“Compensation and Human Capital Committee Report”
Performance markers
Metric facts
revenue
$824.5 million
“total stockholder return metric was January 1, 2023 to December 31, 2025, and the revenue and adjusted EPS metrics were measured based on 2025 results. In February 2026, the CHCC reviewed the achievement of the performan…”
operating income
$15.3 million
“select managed Medicaid populations in 2024. The achievement payout levels for threshold, target, and maximum performance levels were 50%, 100%, and 150%, respectively, of the target bonus amount. As shown below, in Febr…”
say on pay
92%
“votes cast in favor of our Say-on-Pay resolution at our 2025 Annual Meeting of Stockholders.”
ceo pay ratio
60 to 1
“Table due to (i) not including the salary Mr. Raha earned in 2025 while serving as Chief Operating Officer and (ii) including the estimated salary Mr. Raha would have earned as Chief Executive Officer if he had started s…”
median employee compensation
$97,407
“All international employees were excluded in the 5% de minimis exemption adjustment as permitted by SEC rules. We then selected our median employee based on the W-2 calculated income of our U.S. employees for the year en…”
Ask
Anything about MYRIAD GENETICS INC’s 2026 proxy
Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.
Loading the Ask interface…